Darexaban
- Generic Name
- Darexaban
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30N4O4
- CAS Number
- 365462-23-3
- Unique Ingredient Identifier
- KF322K101S
- Background
Darexaban has been used in trials studying the prevention and basic science of Japanese, Caucasian, Thromboembolism, Pharmacodynamics, and Pharmacokinetics, among others.
- Associated Conditions
- -
- Associated Therapies
- -
To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their Effects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01424332
- Locations
- π«π·
SGS Aster, Paris, France
To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01409603
- Locations
- π«π·
SGS Aster, Paris, France
To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 100
- Registration Number
- NCT01409616
- Locations
- π«π·
SGS Aster, Paris, France
To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01406002
- Locations
- π«π·
SGS Aster, Paris, France
To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01405989
- Locations
- π«π·
SGS Aster, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2024. All Rights Reserved by MedPath